In patients living with HIV, seborrheic dermatitis (SD) presents a distinct clinical challenge. This protocol addresses the management approach for this specific population.
In HIV-infected patients, SD is generally not only more prevalent but also more severe than usual, and is frequently associated with a relapsing course. The underlying immune status is a key determinant of disease severity and response to treatment.
In moderate-to-severe presentations in this population, the therapeutic strategy extends beyond conventional topical measures and addresses the underlying immunological status. A systemic approach targeting CD4+ levels is part of the management framework — the full protocol details this further.
Control of CD4+ values and clinically meaningful improvement of seborrheic dermatitis.
In HIV-infected patients, SD is generally not only more prevalent but also more severe than usual, and frequently associated to a relapsing course.
In case of moderate-to-severe SD, the therapy may be challenging, as these forms generally show poor response to topical and systemic antifungals and/or to mid- to high-potency corticosteroids.
In these cases, the control of CD4+ values with antiretroviral drugs may be helpful to achieve SD improvement.
DOI: 10.2147/CCID.S284671
View source ↗